Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Nykode Therapeutics AS's quarterly market cap
increased
from Sep. 2025 (kr551.86 Mil) to Dec. 2025 (kr787.63 Mil) and
increased
from Dec. 2025 (kr787.63 Mil) to Mar. 2026 (kr1,061.27 Mil).
Nykode Therapeutics AS's annual market cap
declined
from Dec. 2023 (kr6,988.08 Mil) to Dec. 2024 (kr994.66 Mil) and
declined
from Dec. 2024 (kr994.66 Mil) to Dec. 2025 (kr787.63 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Nykode Therapeutics AS's Enterprise Value for Today is kr571.76 Mil.
Nykode Therapeutics AS (OSL:NYKD) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSL:NYKD vs VRTX, REGN, RVMD: Market Cap Comparison
For the Biotechnology subindustry, Nykode Therapeutics AS's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nykode Therapeutics AS Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Nykode Therapeutics AS's Market Cap distribution charts can be found below:
* The bar in red indicates where Nykode Therapeutics AS's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Nykode Therapeutics AS's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nykode Therapeutics AS (OSL:NYKD) has a Market Cap of kr1,044.95 Mil as of Jul. 29, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Nykode Therapeutics AS and its competitors. According to the industry distribution chart, Nykode Therapeutics AS ranks #720 out of 1421 companies in the Biotechnology industry, placing it in the top 50.7%.
Is Nykode Therapeutics AS's Market Cap too high?
Nykode Therapeutics AS's current Market Cap is kr1,044.95 Mil. Based on the distribution chart, Nykode Therapeutics AS ranks #720 out of 1421 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Nykode Therapeutics AS has a GF Score™ of 48/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Nykode Therapeutics AS's Market Cap compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Nykode Therapeutics AS ranks #720 out of 1421 companies for Market Cap. This places Nykode Therapeutics AS in the lower half of its industry. The industry median Market Cap is 111.82. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 111.82, based on 1,421 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Nykode Therapeutics AS and its competitors. For the Biotechnology industry, the median Market Cap is 111.82 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nykode Therapeutics AS's current Market Cap is kr1,044.95 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nykode Therapeutics AS stock overvalued right now?
Based on GuruFocus' analysis, Nykode Therapeutics AS (OSL:NYKD) is currently considered Possible Value Trap. The stock's GF Value™ is kr6.45, compared to a current price of kr3.20 — trading 50.4% below its estimated fair value. The current Market Cap is kr1,044.95 Mil. Nykode Therapeutics AS's overall GF Score™ is 48/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Nykode Therapeutics AS (OSL:NYKD), the current Market Cap is kr1,044.95 Mil as of Jul. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Nykode Therapeutics AS (OSL:NYKD) Overvalued in 2026?
Based on GuruFocus' analysis, Nykode Therapeutics AS stock appears to be undervalued.
The current stock price of kr3.20 is trading 50.4% below its estimated GF Value™ of kr6.45.
GuruFocus considers Nykode Therapeutics AS to be Possible Value Trap.
Key valuation signals for OSL:NYKD:
Market Cap: kr1,044.95 Mil
GF Value™: kr6.45 vs. price of kr3.20 (50.4% below fair value)
No single metric tells the full story. See the OSL:NYKD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Nykode Therapeutics AS is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immunotherapies. The company is developing individualized cancer neoantigen vaccines and is using the Vaccibody technology to generate therapeutics to treat cancers with a high unmet medical need using it's modular immunotherapy technology, specifically targeting antigens to Antigen Presenting Cells, which are essential for inducing rapid and long-lasting immune responses. It operates in United States of America.
48GF Score
Get the complete analysis for OSL:NYKD
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSL:NYKD has been successfully added to your 
